Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Erik Škof) .

1 - 10 / 55
First pagePrevious page123456Next pageLast page
1.
Primary pulmonary choricarcinoma
Žiga Snoj, Igor Kocijančič, Erik Škof, 2017, review article

Abstract: The aim of the study was to establish whether there are different clinical entities of primary pulmonary choriocarcinoma (PPC) that deserve different diagnostic approach and the most optimal treatment. Patients and methods. A systematic review with PubMed search was conducted to identify studies that reported cases of PPC. The eligibility criteria were histological diagnosis of pulmonary choriocarcinoma and thorough examination of the reproductive organs to exclude potential primary choriocarcinoma in the gonads. Furthermore, to illustrate the review we additionally present a patient referred at our institution. Results. 55 cases (17 men) were included in the review with a median age of 34 years. Women with the history of gestational event showed better survival outcome than women without the history of gestational event. Patients treated with combined modality treatment (surgery and chemotherapy) survived longer than the patients without combined modality treatment. Furthermore, multivariate analysis of prognostic factors showed that the combined modality treatment had independent prognostic significance. Size of the tumour showed significant prognostic influence in univariate and multivariate analysis. Conclusions. PPC is an extreme rarity with variable clinical characteristics and outcome. It is important to capture and treat patients in the early stages of the disease. Women with the history of gestational event may show better survival, therefore genetic examination could help us to predict patient%s prognosis. Surgery followed by adjuvant chemotherapy appears to represent the best treatment for PPC.
Keywords: choriocarcinoma, gestational event, pulmonary tumor, primary horiokarcinom
Published in DiRROS: 10.05.2024; Views: 91; Downloads: 33
.pdf Full text (552,36 KB)

2.
The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
Erik Škof, Sebastjan Merlo, Gašper Pilko, Borut Kobal, 2016, original scientific article

Abstract: Primary treatment of patients with advanced epithelial ovarian cancer consists of chemotherapy either before (neoadjuvant chemotherapy, NACT) or after primary surgery (adjuvant chemotherapy). The goal of primary treatment is no residual disease after surgery (R0 resection) what is associated with an improvement in survival of patients. There is, however, no evidence of survival benefits in patients with R0 resections after prior NACT. Methods. We retrospectively reviewed the records of patients who were treated with diagnosis of epithelial ovarian cancer at Institute of Oncology Ljubljana in the years 2005%2007. The differences in the rates of R0 resections, progression free survival (PFS), overall survival (OS) and in five-year and eight-year survival rates between patients treated with NACT and patients who had primary surgery were compared. Results. Overall 160 patients had stage IIIC epithelial ovarian cancer. Eighty patients had NACT and eighty patients had primary surgery. Patients in NACT group had higher rates of R0 resection (42% vs. 20%; p = 0.011) than patients after primary surgery. PFS was 14.1 months in NACT group and 17.7 months after primary surgery (p = 0.213). OS was 24.8 months in NACT group and 31.6 months after primary surgery (p = 0.012). In patients with R0 resections five-year and eight-year survival rates were 20.6% and 17.6% in NACT group compared to 62.5% and 62.5% after primary surgery (p < 0.0001), respectively. Conclusions. Despite higher rates of R0 resections achieved by NACT, survival of patients treated with NACT was inferior to survival of patients who underwent primary surgery. NACT should only be offered to patients with advanced epithelial cancer who are not candidates for primary surgery.
Keywords: ovarian cancer, advanced ovarian cancer, neoadjuvant chemotherapy, primary surgery
Published in DiRROS: 30.04.2024; Views: 163; Downloads: 39
.pdf Full text (597,52 KB)

3.
Rak telesa maternice : vzdrževalno zdravljenje z navtemadlinom, zaviralcem MDM2
Ana Geltar, Erik Škof, 2024, published professional conference contribution

Keywords: internistična onkologija, rak telesa maternice, kemoterapija
Published in DiRROS: 22.04.2024; Views: 104; Downloads: 30
.pdf Full text (903,42 KB)

4.
Gen P53 - nova terapevtska tarča za zdravljenje raka telesa maternice
Erik Škof, 2024, published professional conference contribution

Keywords: internistična onkologija, rak telesa maternice, kemoterapija
Published in DiRROS: 19.04.2024; Views: 156; Downloads: 28
.pdf Full text (950,86 KB)

5.
Dnevi internistične onkologije 2024 : inovativna zdravila v onkologiji
2024, proceedings of professional or unreviewed scientific conference contributions

Published in DiRROS: 04.04.2024; Views: 198; Downloads: 70
.pdf Full text (9,80 MB)

6.
7.
Rak jajčnikov : kaj morate vedeti o bolezni
Brigita Gregorič, Erik Škof, Breda Škrbinc, 2023, not set

Keywords: dejavniki tveganja, simptomi, diagnostika, zdravljenje, neželeni učinki
Published in DiRROS: 06.03.2024; Views: 133; Downloads: 35
.pdf Full text (1,84 MB)

8.
Naše izkušnje s PARP inhibitorji pri raku jajčnikov na OI Ljubljana
Erik Škof, 2023, published scientific conference contribution

Keywords: rak jajčnikov, sistemsko zdravljenje, ginekološki raki
Published in DiRROS: 23.11.2023; Views: 241; Downloads: 126
.pdf Full text (340,15 KB)
This document has many files! More...

9.
Imunoterapija pri raku telesa maternice
Erik Škof, 2023, published scientific conference contribution

Abstract: Nova molekularna klasifikacija raka telesa maternice je omogočila novo, usmerjeno zdravljenje bolnic z rakom telesa maternice. Glavno novost predstavlja imunoterapija z zaviralci imunskih nadzornih točk (zaviralci PD-1) pri bolnicah z metastatskim rakom telesa maternice v 2. liniji zdravljenja, po predhodnem zdravljenu s kemoterapijo. Evropska agencija za zdravila (EMA) je odobrila uporabo dveh zaviralcev PD-1 receptorjev - dostarlimab in pembrolizumab v monoterapiji v primeru, da gre za okvaro MMR proteinov v tumorju (dMMR/MSI-H karcinom). Odobrena je tudi kombinacija pembrolizumaba in lenvatiniba (zaviralec tirozin kinaz) v 2. liniji zdravljenja metastatske bolezni, po predhodnem zdravljenju s kemoterapijo, ne glede na status MMR proteinov, torej tudi v primeru, da ne gre za okvaro MMR proteinov v tumorju (pMMR/MSS karcinom). Pred kratkim so bili objavljeni rezultati, ki kažejo učinkovitost pembrolizumaba in dostarlimaba v kombinaciji s kemoterapijo v 1. liniji napredovale ali metastatske bolezni. V adjuvantnem zdravljenju zaenkrat še nimamo podatkov o učinkovitosti imunoterapije - potekajo klinične raziskave.
Keywords: rak maternice, ginekološki raki, ginekološka onkologija
Published in DiRROS: 30.05.2023; Views: 348; Downloads: 138
.pdf Full text (281,13 KB)
This document has many files! More...

10.
Neželeni učinki sistemskega zdravljenja raka
Erik Škof, 2022, published scientific conference contribution

Abstract: Pri beleženju neželenih učinkov sistemskega zdravljenja uporabljamo mednarodne kriterije “Common Terminology Criteria for Adverse Events”, ki jih je ustanovil Ameriški Nacionalni inštitut za zdravljenje raka. V prispevku prikazujemo definicije izrazov, ki jih uporabljamo pri opisovanju in vrednotenju neželenih učinkov zdravljenja. Po Zakonu o zdravilih in Pravilniku o farmakovigilanci zdravil za uporabo v humani medicini je poročanje o domnevnih neželenih učinkih za zdravstvene delavce obvezno. Prikazujemo osnovna navodila in informacije za prijavo neželenih učinkov zdravljenja.
Keywords: neželeni učinki, bolniki, sistemsko zdravljenje
Published in DiRROS: 17.01.2023; Views: 453; Downloads: 115
.pdf Full text (69,50 KB)

Search done in 0.38 sec.
Back to top